Review: Therapeutic Drug Monitoring of Antiretroviral Therapy
- 1 January 2004
- journal article
- case report
- Published by Mary Ann Liebert Inc in AIDS Patient Care and STDs
- Vol. 18 (1), 7-14
- https://doi.org/10.1089/108729104322740866
Abstract
The concept of managing pharmacotherapy based on plasma drug concentrations has been used for decades in a variety of clinical settings. The interest in therapeutic drug monitoring (TDM) of antiretroviral drugs has grown significantly since highly active antiretroviral therapy (HAART) became a standard of care in clinical practice. A primary characteristic of TDM of antiretroviral drugs is that multiple agents are concomitantly used in HAART regimens. Inadequate drug concentrations may lead to evolution of drug resistance mutations and endanger present and future treatment options. A number of clinical trials have demonstrated that drug serum concentrations are an important factor in response to therapy for HIV, but whether TDM will become a tool for the routine management of HIV infection remains to be determined. This review includes an illustrative case report of measuring concentrations of antiretroviral drugs in a pediatric patient.Keywords
This publication has 42 references indexed in Scilit:
- Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometryJournal of Mass Spectrometry, 2003
- Therapeutic Drug MonitoringDrugs, 2003
- Position Paper on Therapeutic Drug Monitoring of Antiretroviral AgentsAIDS Research and Human Retroviruses, 2002
- Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver diseaseBritish Journal of Clinical Pharmacology, 2000
- A Clinical Study of the Combination of 100 mg Ritonavir plus 800 mg Indinavir as Salvage Therapy: Influence of Increased Plasma Drug Levels in the Rate of ResponseHIV Research & Clinical Practice, 2000
- Systemic Pharmacokinetics and Cellular Pharmacology of Zidovudine in Human Immunodeficiency Virus Type 1–Infected Women and Newborn InfantsThe Journal of Infectious Diseases, 1999
- The Effect of Increasing α1‐Acid Glycoprotein Concentration on the Antiviral Efficacy of Human Immunodeficiency Virus Protease InhibitorsThe Journal of Infectious Diseases, 1999
- Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV InfectionClinical Pharmacokinetics, 1999
- Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug InteractionsJournal of Pharmaceutical Sciences, 1998
- Protease Inhibitors in Patients with HIV DiseaseClinical Pharmacokinetics, 1997